Top 3 Countries
China
Country
Rank |
Revenue
CY 2010 |
%
Share
in 2010 |
1-3 |
13675.73 |
48.04 |
4-5 |
2488.81 |
8.74 |
6-10 |
3427.09 |
12.04 |
11-20 |
3804.46 |
13.37 |
Others |
5068.37 |
17.81 |
Grand
Total |
28464.46 |
100 |
India
Country
Rank |
Revenue
CY 2010 |
%
Share
in 2010 |
1-3 |
3854.06 |
20.97 |
4-5 |
1795.03 |
9.77 |
6-10 |
3045.04 |
16.57 |
11-20 |
3440.83 |
18.72 |
Others |
6245.1 |
33.98 |
Grand
Total |
18380.06 |
100 |
Australia
Country
Rank |
Revenue
CY
2010 |
%
Share
in
2010 |
1-3 |
8949.74 |
85.03 |
4-5 |
849.85 |
8.07 |
6-10 |
354.31 |
3.37 |
11-20 |
227.74 |
2.16 |
Others |
143.53 |
1.36 |
Grand
Total |
10525.17 |
100 |
Legend: Country Rank: Publicly
listed companies in the particular country; Revenue CY 2010: Revenue
for the calender year 2010; % Share in 2010: Companies’ percentage
share in the total revenue of publicly listed companies country wise
China leads with five companies having revenues in excess of $1
billion. In fact, China’s No. 1 company, Sinopharm, which is also
Asia’s No. 1 company for the second consecutive year in 2010 has grown
by 48 percent and crossed the $10 billion revenue milestone. In
addition to Sinopharm, other Chinese companies have also grown at a
fast clip – North China Pharmaceutical (113 percent growth), Yunnan
Baiyao Group (78 percent growth), and Shenzhen Neptunus Bioengineer
grew by a remarkable 51 percent. This is a sampling of the boom that is
happening in China.
Compared to this, India, the other fast growing market in the region,
has just two billion dollar companies among the country’s Top 20 list,
however, a bunch of stable growing companies make up the rest of the
industry. Australia has three companies over a billion dollars. And
among other regions, it is likely that a couple of South Korean
companies may cross this milestone in 2011. China, India, Australia
continue to remain the Top 3 countries in the region, closely followed
by South Korea and the
others.
The global pharma players have already recognized the opportunities
available in China’s fast growing pharmaceutical market. Sanofi-Aventis
expanded its R&D presence in China by opening a new research
center. Eli Lilly announced plans to launch 15 new products in China
over the next five years. And Medtronics started its operation in China.
With an increase in investment and competition from multinationals, the
local big pharma companies are preparing to face new challenges in the
growing market. Consolidation is being adopted as one of the strategies
by the local pharma companies to counter the competition from
multinationals.